# Climb Bio, Inc.: financial statements, quarterly

CLYM · Nasdaq · CIK 1768446 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/clym.md) · [Financials](/companies/clym/financials.md) · [Filings](/companies/clym/filings.md) · [Insiders](/companies/clym/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/clym/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [2.9](/filings/0000950170-24-125294.md) | [3.1 d](/filings/0000950170-25-044350.md) | [1.1](/filings/0000950170-25-070902.md) | [1.0](/filings/0000950170-25-106916.md) | [6.2](/filings/0001193125-25-268086.md) | [6.0 d](/filings/0001193125-26-092546.md) | [17.3](/filings/0001193125-26-210357.md) | [6.6](/filings/0001193125-26-336774.md) | [9.1](/filings/0001193125-25-268086.md) | [13.7 d](/filings/0001193125-26-092546.md) | [9.4](/filings/0001193125-26-210357.md) | [9.7](/filings/0001193125-26-336774.md) |
| Operating income | $m | [(5.0)](/filings/0000950170-24-125294.md) | [(5.1) d](/filings/0000950170-25-044350.md) | [(3.0)](/filings/0000950170-25-070902.md) | [(56.4)](/filings/0000950170-25-106916.md) | [(11.7)](/filings/0001193125-25-268086.md) | [(10.9) d](/filings/0001193125-26-092546.md) | [(23.0)](/filings/0001193125-26-210357.md) | [(10.7)](/filings/0001193125-26-336774.md) | [(14.9)](/filings/0001193125-25-268086.md) | [(19.3) d](/filings/0001193125-26-092546.md) | [(15.2)](/filings/0001193125-26-210357.md) | [(15.4)](/filings/0001193125-26-336774.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-125294.md) | [0.0 d](/filings/0000950170-25-044350.md) | [0.0](/filings/0000950170-25-070902.md) | [0.0 d](/filings/0000950170-24-096626.md) | [0.0](/filings/0000950170-24-125294.md) | [0.0 d](/filings/0001193125-26-092546.md) | [0.0](/filings/0000950170-25-070902.md) | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(4.0)](/filings/0000950170-24-125294.md) | [(3.6) d](/filings/0000950170-25-044350.md) | [(1.7)](/filings/0001193125-25-268086.md) | [(54.9)](/filings/0001193125-25-268086.md) | [(8.9)](/filings/0001193125-25-268086.md) | [(8.4) d](/filings/0001193125-26-092546.md) | [(20.8)](/filings/0001193125-26-336774.md) | [(8.7)](/filings/0001193125-26-336774.md) | [(12.9)](/filings/0001193125-25-268086.md) | [(17.5) d](/filings/0001193125-26-092546.md) | [(13.7)](/filings/0001193125-26-336774.md) | [(13.5)](/filings/0001193125-26-336774.md) |
| Diluted EPS | $ per share | [(0.15)](/filings/0000950170-24-125294.md) | not reported | [(0.06)](/filings/0000950170-25-070902.md) | [(1.81)](/filings/0000950170-25-106916.md) | [(0.13)](/filings/0001193125-25-268086.md) | not reported | [(0.31)](/filings/0001193125-26-210357.md) | [(0.13)](/filings/0001193125-26-336774.md) | [(0.19)](/filings/0001193125-25-268086.md) | not reported | [(0.20)](/filings/0001193125-26-210357.md) | [(0.18)](/filings/0001193125-26-336774.md) |
| Basic EPS | $ per share | [(0.15)](/filings/0000950170-24-125294.md) | not reported | [(0.06)](/filings/0000950170-25-070902.md) | [(1.81)](/filings/0000950170-25-106916.md) | [(0.13)](/filings/0001193125-25-268086.md) | not reported | [(0.31)](/filings/0001193125-26-210357.md) | [(0.13)](/filings/0001193125-26-336774.md) | [(0.19)](/filings/0001193125-25-268086.md) | not reported | [(0.20)](/filings/0001193125-26-210357.md) | [(0.18)](/filings/0001193125-26-336774.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [57.4](/filings/0000950170-23-063675.md) | [93.1](/filings/0000950170-25-044350.md) | [105](/filings/0000950170-24-059995.md) | [223](/filings/0000950170-24-096626.md) | [146](/filings/0000950170-24-125294.md) | [87.2](/filings/0001193125-26-092546.md) | [29.0](/filings/0000950170-25-070902.md) | [22.7](/filings/0001193125-26-336774.md) | [25.8](/filings/0001193125-25-268086.md) | [35.7](/filings/0001193125-26-336774.md) | [8.4](/filings/0001193125-26-210357.md) | [44.1](/filings/0001193125-26-336774.md) |
| Current assets | $m | [112](/filings/0000950170-23-063675.md) | [110](/filings/0000950170-25-044350.md) | [109](/filings/0000950170-24-059995.md) | [226](/filings/0000950170-24-096626.md) | [198](/filings/0000950170-24-125294.md) | [155](/filings/0001193125-26-092546.md) | [100](/filings/0000950170-25-070902.md) | [87.4](/filings/0000950170-25-106916.md) | [91.0](/filings/0001193125-25-268086.md) | [106](/filings/0001193125-26-336774.md) | [113](/filings/0001193125-26-210357.md) | [187](/filings/0001193125-26-336774.md) |
| Total assets | $m | [113](/filings/0000950170-23-063675.md) | [110](/filings/0000950170-25-044350.md) | [109](/filings/0000950170-24-059995.md) | [226](/filings/0000950170-24-096626.md) | [222](/filings/0000950170-24-125294.md) | [217](/filings/0001193125-26-092546.md) | [201](/filings/0000950170-25-070902.md) | [192](/filings/0000950170-25-106916.md) | [182](/filings/0001193125-25-268086.md) | [168](/filings/0001193125-26-336774.md) | [152](/filings/0001193125-26-210357.md) | [246](/filings/0001193125-26-336774.md) |
| Current liabilities | $m | [2.9](/filings/0000950170-23-063675.md) | [2.8](/filings/0000950170-25-044350.md) | [3.0](/filings/0000950170-24-059995.md) | [3.7](/filings/0000950170-24-096626.md) | [3.4](/filings/0000950170-24-125294.md) | [4.9](/filings/0001193125-26-092546.md) | [7.0](/filings/0000950170-25-070902.md) | [6.2](/filings/0000950170-25-106916.md) | [4.9](/filings/0001193125-25-268086.md) | [7.0](/filings/0001193125-26-336774.md) | [4.1](/filings/0001193125-26-210357.md) | [5.9](/filings/0001193125-26-336774.md) |
| Total liabilities | $m | [3.0](/filings/0000950170-23-063675.md) | [2.9](/filings/0000950170-25-044350.md) | [3.0](/filings/0000950170-24-059995.md) | [3.7](/filings/0000950170-24-096626.md) | [3.4](/filings/0000950170-24-125294.md) | [5.3](/filings/0001193125-26-092546.md) | [7.4](/filings/0000950170-25-070902.md) | [6.6](/filings/0000950170-25-106916.md) | [5.3](/filings/0001193125-25-268086.md) | [7.3](/filings/0001193125-26-336774.md) | [4.3](/filings/0001193125-26-210357.md) | [6.7](/filings/0001193125-26-336774.md) |
| Shareholders' equity | $m | [110](/filings/0000950170-24-125294.md) | [108](/filings/0001193125-26-092546.md) | [106](/filings/0001193125-25-268086.md) | [222](/filings/0001193125-25-268086.md) | [219](/filings/0001193125-25-268086.md) | [212](/filings/0001193125-26-336774.md) | [193](/filings/0001193125-26-336774.md) | [186](/filings/0001193125-26-336774.md) | [177](/filings/0001193125-25-268086.md) | [160](/filings/0001193125-26-336774.md) | [148](/filings/0001193125-26-336774.md) | [240](/filings/0001193125-26-336774.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [3.5 d](/filings/0000950170-24-125294.md) | [(0.9) d](/filings/0000950170-25-044350.md) | [(1.8)](/filings/0000950170-25-070902.md) | [(0.7) d](/filings/0000950170-25-106916.md) | [(7.6) d](/filings/0001193125-25-268086.md) | [(5.5) d](/filings/0001193125-26-092546.md) | [(15.4)](/filings/0001193125-26-210357.md) | [(11.1) d](/filings/0001193125-26-336774.md) | [(12.1) d](/filings/0001193125-25-268086.md) | [(15.6) d](/filings/0001193125-26-092546.md) | [(14.4)](/filings/0001193125-26-210357.md) | [(10.5) d](/filings/0001193125-26-336774.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-125294.md) | [0.0 d](/filings/0000950170-25-044350.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-268086.md) | [0.0 d](/filings/0001193125-26-092546.md) | not reported | not reported | [0.1 d](/filings/0001193125-25-268086.md) | [0.0 d](/filings/0001193125-26-092546.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [26.3](/filings/0000950170-23-063675.md) | [26.5](/filings/0000950170-24-059995.md) | [26.8](/filings/0000950170-24-096626.md) | [27.1](/filings/0000950170-24-125294.md) | [27.6](/filings/0000950170-25-070902.md) | [30.3](/filings/0000950170-25-106916.md) | [67.0](/filings/0001193125-25-268086.md) | [67.5](/filings/0001193125-26-210357.md) | [67.6](/filings/0001193125-26-336774.md) | [68.0](/filings/0001193125-25-268086.md) | [68.2](/filings/0001193125-26-210357.md) | [76.2](/filings/0001193125-26-336774.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 57,436,255 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336774.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.